CELZ on Nasdaq
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Allogene Therapeutics, Inc., Senti Biosciences Holdings, Inc. or Opthea Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
63.4%Gross margin3
-102380.2%Operating margin3
-99916.8%Net margin3
-45.5%Revenue growth, 20253
-79.8%Return on equity3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$2.2K
- Research and development38¢$2.3M
- Selling, general and admin62¢$3.8M
Out of $6.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $6.0K | $11.0K |
| Cost of revenues | $2.2K | $4.4K |
| Gross profit | $3.8K | $6.6K |
| Research and development | $2.3M | $2.4M |
| Selling, general and administrative | $3.8M | $3.2M |
| Amortization of patent costs | $123.3K | $110.5K |
| TOTAL EXPENSES | $6.1M | $5.8M |
| Operating loss | -$6.1M | -$5.7M |
| Interest income | $147.8K | $250.4K |
| Total other income (expense) | $147.8K | $250.4K |
| LOSS BEFORE PROVISION FOR INCOME TAXES | -$6.0M | -$5.5M |
| Provision for income taxes | $0 | $0 |
| NET LOSS | -$6.0M | -$5.5M |
| Net income attributable to non-controlling interest | $0 | $0 |
| NET LOSS ATTRIBUTABLE TO CMTH | -$6.0M | -$5.5M |
| NET LOSS PER SHARE - BASIC AND DILUTED | -$2.52 | -$3.71 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED | 2.4M shares | 1.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $7.2M | $5.9M | $3.5M |
| Inventory | $0 | $2.2K | |
| Note receivable, net of premium | $52.1K | $0 | |
| Prepaids and other current assets | $138.8K | $192.7K | |
| Total Current Assets | $7.4M | $6.1M | |
| Other assets | $3.3K | $3.3K | |
| Licenses, net of amortization | $407.2K | $530.6K | |
| TOTAL ASSETS | $7.8M | $6.7M | |
| Accounts payable | $270.7K | $273.5K | |
| Accrued expenses | $0 | $39.9K | |
| Advances from related party | $14.2K | $14.2K | |
| Total Current Liabilities | $284.9K | $327.6K | |
| TOTAL LIABILITIES | $284.9K | $327.6K | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value, 25,000,000 shares authorized; 3,701,668 and 1,748,428 issued and 3,696,668 and 1,748,428 outstanding at December 31, 2025 and 2024, respectively | $3.1K | $1.7K | |
| Additional paid-in capital | $78.1M | $70.9M | |
| Accumulated deficit | -$70.6M | -$64.6M | |
| Treasury stock, at cost, 5,000 and 0 shares as of December 31, 2025 and 2024, respectively | -$10.0K | $0 | |
| TOTAL STOCKHOLDERS' EQUITY | $7.5M | $6.3M | |
| Non-controlling interest | $10.0K | $0 | |
| TOTAL EQUITY ATTRIBUTABLE TO CMTH | $7.5M | $6.3M | $10.3M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $7.8M | $6.7M | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 25.0M shares | 25.0M shares | |
| Common stock, shares issued | 3.7M shares | 1.7M shares | |
| Common stock, shares outstanding | 3.7M shares | 1.7M shares | |
| Treasury stock, cost | 5.0K shares | 0 shares | |
| Preferred stock, shares par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$6.0M | -$5.5M |
| Stock-based compensation | $3.5K | $36.6K |
| Amortization of intangible assets | $123.3K | $110.5K |
| Amortization of note receivable premium | -$1.6K | $0 |
| Inventory | $2.2K | $4.4K |
| Prepaids and other current assets | $53.9K | $84.5K |
| Accounts payable | -$2.8K | -$43.9K |
| Accrued expenses | -$39.9K | $0 |
| Advances from related party | $0 | $0 |
| Net cash used in operating activities | -$5.9M | -$5.3M |
| Issuance of note receivable | -$50.5K | $0 |
| Redemptions of investments | $0 | $6.5M |
| Payment of patent purchase obligation - related party | $0 | -$200.0K |
| Net cash provided by (used in) investing activities | -$50.5K | $6.3M |
| Contribution from minority member | $10.0K | $0 |
| Purchase of treasury stock | -$10.0K | -$175.0K |
| Proceeds from sale of common stock and warrants, net of issuance costs | $7.2M | $1.6M |
| Proceeds from sale of Series B preferred stock | $0 | $100 |
| Net cash provided by financing activities | $7.2M | $1.5M |
| NET CHANGE IN CASH | $1.3M | $2.5M |
| Cash payments for interest | $0 | $0 |
| Cash payments for income taxes | $0 | $0 |
| Cancellation of Series B preferred stock within accounts payable | $0 | $100 |
| Cancellation of treasury stock | $0 | $445.9K |
Compare CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. with another company
Former names
- JOLLEY MARKETING INCSep 13, 2002 to May 13, 20162
Recent filings
- Oct 1, 2026SCHEDULE 13D
- Sep 25, 20268-K
- Sep 25, 20264
- Aug 31, 20268-K
- Aug 7, 202610-Q
- Aug 3, 2026424B3
- Jul 31, 2026EFFECT
- Jul 24, 2026S-3
- Jul 14, 2026DEF 14A
- Jul 2, 20268-K
- Jul 1, 2026PRE 14A
- Jun 30, 2026RW
- Jun 26, 2026S-1/A
- Jun 25, 2026S-1
- May 28, 2026DRS
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10